<DOC>
	<DOCNO>NCT02159053</DOCNO>
	<brief_summary>The purpose study provide 16-week efficacy , safety tolerability data versus placebo support use secukinumab 150 mg subcutaneous ( s.c. ) self-administration without load regimen maintenance dose use pre-filled syringe ( PFS ) ass efficacy , safety tolerability 2 year subjects active AS despite current previous NSAID , non-biologic DMARD , biologic anti-TNFÎ± therapy .</brief_summary>
	<brief_title>16-week Efficacy 2-year Safety , Tolerability Efficacy Secukinumab Participants With Active Ankylosing Spondylitis</brief_title>
	<detailed_description />
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion criterion : moderate severe AS , prior radiographic evidence accord Modified NY Criteria ( 1984 ) , inadequate response NSAIDs . Exclusion criterion : pregnancy lactation , ongoing infectious malignant process chest Xray MRI , previous exposure IL17 IL17R target therapy , previous exposure biological immunomodulating agent exclude TNF antagonist , previous cell deplete therapy . Other protocoldefined inclusion/exclusion criterion apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>AIN457 , ankylose spondylitis , chronic inflammatory disease , inflammatory back pain , secukinumab , self-injection</keyword>
</DOC>